Intravenous administration of ACE inhibitors
Pro Research Analysisby 
Searched over 200M research papers
Intravenous ACE Inhibitors: Hemodynamic Effects and Clinical Applications
Hemodynamic Effects of Intravenous ACE Inhibitors
Intravenous (IV) administration of ACE inhibitors, such as enalaprilat, quinaprilat, and perindoprilat, has been shown to cause significant reductions in mean arterial pressure (MAP) and systemic vascular resistance (SVR), with effects being dose-dependent. High doses of enalaprilat result in greater decreases in MAP and SVR compared to lower doses, and also lead to increased venous pooling, indicating both arterial and venous vasodilation. These changes can improve microcirculation as long as blood pressure does not fall excessively . Similarly, IV quinaprilat in patients after coronary artery bypass grafting (CABG) with poor left ventricular function increased cardiac output and left ventricular stroke work index, while reducing systolic blood pressure and pulmonary vascular resistance, without significant changes in heart rate or diastolic blood pressure . In normotensive volunteers, low-dose IV perindoprilat infusions produced significant blood pressure reductions without affecting heart rate, and the pharmacokinetics allowed for dose titration to optimize therapy .
Use in Cardiac Surgery and Heart Failure
IV ACE inhibitors are particularly useful in perioperative and intensive care settings, especially for patients unable to take oral medications. In cardiac surgery, acute administration of IV quinaprilat lowered systemic vascular resistance index without increasing the risk of hypotensive episodes or affecting proinflammatory cytokine levels, suggesting a favorable hemodynamic profile during and after surgery . Case reports also highlight the benefit of IV enalaprilat in managing intraoperative heart failure, with documented improvements in cardiac function and hemodynamics . For patients with impaired left ventricular function post-CABG, IV quinaprilat provided optimal hemodynamic support and may help prevent heart failure progression .
Transition from Oral to Intravenous ACE Inhibitors
Switching from oral ACE inhibitors to IV quinaprilat in patients with mild to moderate hypertension maintained effective blood pressure control. IV quinaprilat, administered at half the oral dose, was well tolerated and allowed for safe conversion, which is important for patients in intensive care or perioperative settings who cannot take oral medications .
Pharmacologic and Therapeutic Considerations
Among ACE inhibitors, enalaprilat is the only agent available in an IV formulation and does not require hepatic activation, making it suitable for patients with severe liver dysfunction. The pharmacokinetic profiles of IV ACE inhibitors allow for individualized dosing and titration, which is beneficial in acute care settings .
Management of Overdose and Vasopressor Response
In cases of ACE inhibitor overdose, most patients respond to supportive care with IV fluids, but in rare cases where blood pressure is not controlled, IV angiotensin II may be effective . In critically ill patients on chronic ACE inhibitor therapy, the hemodynamic response to vasopressin is similar to those not on ACE inhibitors, with only a transient difference in MAP at 6 hours post-initiation .
Conclusion
IV administration of ACE inhibitors provides effective and flexible hemodynamic management in acute and perioperative settings, especially for patients unable to take oral medications or with specific organ dysfunction. These agents offer dose-dependent vasodilatory effects, improve cardiac output in heart failure, and can be safely transitioned from oral therapy. Their pharmacologic properties and clinical benefits make them valuable tools in critical care and surgical environments 1234+5 MORE.
Sources and full results
Most relevant research papers on this topic